I am a Clinical Oncology registrar undertaking an MD focussing on improved biomarker-driven risk stratification and prediction of treatment response in Prostate Cancer. I use digital pathology analysis of diagnostic core biopsy H&E slides from large retrospective studies, along with techniques such as multiplex immunofluorescence and TCR sequencing to evaluate the Prostate Cancer tumour and immune landscape, and longitudinal response to radiotherapy.

From enjoying Cancer and Immunology modules in my Imperial College BSc, my Cancer Biology MRes included in vitro CRAF-RAS investigations at the Crick and some unexpected COVID work. My ICR PhD investigated bladder tumour, blood and urine clinical trial samples with genomics, transcriptomics, mIF and flow cytometry, which I’m continuing as a postdoc.

I am a postdoctoral training fellow studying the role of cancer-associated fibroblasts in muscle-invasive bladder cancer. I use multiplex immunofluorescence and digital pathology analysis to quantify the cellular composition and spatial arrangement of cancer-associated fibroblasts in the retrospective clinical trial samples.

Shuang joined Professor Berrington’s research team in November 2025 as a PhD student. She completed a Master of Public Health (MPH) at Imperial College London in September 2025, specialising in environmental and cancer epidemiology. Her research examines how environmental exposures and cancer treatments influence cancer risk and survivorship. She is currently using population-based data to investigate the late effects of paediatric cancer treatment and to help inform guidelines for surveillance and screening strategies for survivors.

I completed my MChem at the University of York in Chemistry, Medicinal and Biological Chemistry, with a year in industry, where I worked at UCB Pharma, in the Medicinal Chemistry department. My Masters project was on a drug discovery project in peptide therapeutics. After this, I completed a 10-week internship in organic chemistry at AstraZeneca. I then worked as a Junior Medicinal Chemist for a year, at Autifony Therapeutics, working in CNS drug discovery. For my PhD, an MRC iCASE-funded project, I aim to develop small molecules targeting the telomeric Shelterin complex, jointly in Sebastian Guettler's and Swen Hoelder's groups at the ICR, with Merck as our industry partner.